Jaguar Health Inc. (JAGX)
JAGX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/0001193125-26-144470-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | JAGX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001585608 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $11.5M |
| Net income | -$53.6M |
| Operating income | -$45.9M |
| Net margin | -465.4% |
| Operating margin | -398.8% |
| Revenue growth | -1.5% |
| Cash | $968K |
| Total assets | $38.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern over the next 12 months after the date these financial statements are issued." | 10-Q 2026-08-19 |
| Cash and burn | $3.8M cash; operating cash flow -$1.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-07-31 |
| Reverse splits, 3 years | 4; latest 1-for-15 on 2026-09-17 | Source 2026-09-17 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-11-09 |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-05-04 |
| Auditor | RBSM LLP, LARKSPUR, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-02-20 |
| Late filings, 12 months | 3 NT notices | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $1.2M | -$12.8M | -$5.3M | $3.8M | $29.4M | $27.8M | 10-Q 2026-08-19 |
| Q1 2026 2026-03-31 | $20.3M | $8.7M | $8.8M | $7.3M | $55.2M | $29.6M | 10-Q 2026-05-20 |
| Q4 2025 2025-12-31 | $3.2M | -$23.2M | -$5.5M | $968K | $70.0M | $11.5M | 10-K 2026-04-07 |
| Q3 2025 2025-09-30 | $3.1M | -$9.5M | -$4.7M | $3.5M | $53.9M | $11.8M | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $3.0M | -$10.4M | -$6.2M | $2.2M | $47.9M | $11.8M | 10-Q 2026-08-19 |
| Q1 2025 2025-03-31 | $2.2M | -$10.5M | -$7.3M | $5.7M | $55.7M | $11.6M | 10-Q 2026-05-20 |
| Q4 2024 2024-12-31 | $3.5M | -$9.9M | -$7.8M | $8.0M | $47.6M | $11.7M | 10-K 2026-04-07 |
| Q3 2024 2024-09-30 | $3.1M | -$9.9M | -$6.3M | $13.3M | $44.6M | $10.5M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-09 |
| Latest annual report | 10-K | 2026-04-07 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-10-29 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.7% |
| 1 month | -89.9% |
| 3 months | -96.4% |
| Year to date | -99.9% |
| 1 year | -100.0% |
| From 52-week high | -100.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CNSP | CNS Pharmaceuticals Inc. | $3.48 | +20.42% | $5.1M |
| CVKD | Cadrenal Therapeutics Inc. | $1.40 | -7.28% | $5.0M |
| SCNX | Scienture Holdings Inc. | $2.99 | +3.10% | $4.9M |
| PULM | Pulmatrix Inc. | $1.33 | +2.31% | $4.9M |
| PCSA | Processa Pharmaceuticals Inc. | $1.72 | -7.53% | $4.8M |
| CANF | Can-Fite Biopharma Ltd | $1.56 | +9.86% | $4.7M |
| SKYE | Skye Bioscience Inc. | $1.06 | -2.29% | $4.7M |
| ACXP | Acurx Pharmaceuticals Inc. | $0.9350 | -2.60% | $5.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier